Equillium (EQ) Current Leases (2021 - 2026)
Equillium (EQ) posted quarterly Current Leases of $441000.0 for Q1 2026, up 202.05% year-over-year from $146000.0 in Q1 2025, and up 21.49% quarter-over-quarter from $363000.0 in Q4 2025.
Equillium (EQ) Current Leases (2021 - 2026) Analysis & Trends
Equillium (EQ) has reported Current Leases for 6 consecutive years, with $441000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 202.05% year-over-year to $441000.0; the TTM figure through Mar 2026 stood at $441000.0 (up 202.05% YoY), while the FY2025 annual figure was $363000.0, up 84.26% from the prior year.
- Current Leases advanced to $441000.0 in Q1 2026 per EQ's latest filing, from $363000.0 in the prior quarter.
- Across five years, Current Leases topped out at $441000.0 in Q1 2026 and bottomed at $146000.0 in Q1 2025.
- Historically, Current Leases has averaged $352235.3 across 5 years, with a median of $408000.0 in 2022.
- Annual changes were most pronounced in 2025 — Current Leases sank 65.57% — and 2026, when it jumped 202.05%.
- Equillium's Current Leases stood at $408000.0 in 2022, then increased by 7.84% to $440000.0 in 2023, then slumped by 55.23% to $197000.0 in 2024, then surged by 84.26% to $363000.0 in 2025, then advanced by 21.49% to $441000.0 in 2026.
- Business Quant data shows EQ's Current Leases at $441000.0 in Q1 2026, $363000.0 in Q4 2025, and $272000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 412,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 412,000.00 |
| Mar 31, 2026 | 441,000.00 |
| Dec 31, 2025 | 363,000.00 |
| Sep 30, 2025 | 272,000.00 |
| Jun 30, 2025 | 150,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Sep 30, 2024 | 274,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Mar 31, 2024 | 424,000.00 |
| Dec 31, 2023 | 440,000.00 |
| Sep 30, 2023 | 428,000.00 |
| Jun 30, 2023 | 416,000.00 |
| Mar 31, 2023 | 404,000.00 |
| Dec 31, 2022 | 408,000.00 |
| Sep 30, 2022 | 421,000.00 |
| Jun 30, 2022 | 434,000.00 |
| Mar 31, 2022 | 420,000.00 |
| Dec 31, 2021 | 376,000.00 |